Data_Sheet_1_Bibliometric Analysis of International Scientific Production on Pharmacologic Treatments for SARS-CoV-2/COVID-19 During 2020.docx

BackgroundCOVID-19 is causing a grave global health and economic crisis and the fight against the pandemic has led to unprecedented scientific activity. Bibliometrics could be a useful tool for guiding future researches lines and promoting international collaboration for an effective treatment. For this purpose, we have conducted a bibliometric analysis of scientific publications on drugs and therapies used to treat COVID-19 during 2020.MethodsData source: Web of Science. We gathered data on scientific production relating to drugs used to treat COVID-19. We calculated impact factors and analyzed production by institution, country, and journal, visualizing our results in bibliometric networks.ResultsIn 1 year, production relating to COVID-19 exceeded 100 000 publications, with over 6,500 on Drugs and COVID-19. Research into hydroxychloroquine and chloroquine, remdesivir, lopinavir and ritonavir, tocilizumab and convalescent plasma is particularly noteworthy. Mean citations/study range from 11.9 to 15.4. Producer institutions fall into three groups: one in the US and centered on Harvard Medical School; another in Europe led by INSERS; and another in China led by Huazhong University of Science and Technology. Production by journal is widespread but the Journal of Medical Virology, International Journal of Antimicrobial Agents, and American Journal of Transplantation are noteworthy.ConclusionsThe volume of research that is currently under way is comparable to the magnitude of the pandemic itself. Such a high volume of studies is infrequent and the impact they have achieved has no known precedent. The producing countries are those with highest incidence of the pandemic and greatest scientific potential; moreover, inter-agency and international collaboration has reached extraordinarily high levels.

背景：COVID-19疫情引发了全球性的严重公共卫生和经济危机，抗击疫情的斗争催生了前所未有的科学活动。文献计量学可作为引导未来研究方向和促进国际间有效治疗合作的有用工具。为此，我们对2020年期间用于治疗COVID-19的药物和疗法的科学出版物进行了文献计量分析。
方法：数据来源：Web of Science。我们收集了与用于治疗COVID-19的药物相关的科学研究成果。我们计算了影响因子，并按机构、国家和期刊分析了产出，通过文献计量网络可视化我们的结果。
结果：在一年内，与COVID-19相关的产出超过了10万篇出版物，其中关于药物与COVID-19的研究超过6,500篇。对羟氯喹和氯喹、瑞德西韦、洛匹那韦和利托那韦、托珠单抗和康复期血浆的研究尤为引人注目。平均每项研究的引用次数在11.9至15.4之间。产出机构分为三类：一是以哈佛医学院为中心的美国机构；二是以法国国家健康与医学研究所（INSERS）领导的欧洲机构；三是以华中科技大学领导的我国机构。期刊产出分布广泛，但《医学病毒学杂志》、《国际抗菌素杂志》和《美国移植杂志》值得关注。
结论：正在进行的研究量与疫情的规模相当。如此高密度的研究并不多见，它们所取得的成果也前所未有。产出研究的国家是疫情发生率和科学潜力最高的国家；此外，跨机构和国际间的合作达到了前所未有的高度。